Key terms
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BCRX news
Apr 14
2:36am ET
RBC Capital Keeps Their Buy Rating on BioCryst (BCRX)
Apr 08
11:00pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 03
7:02am ET
BioCryst reports inducement grants under Nasdaq listing rule
Mar 05
7:20am ET
BioCryst reports inducement grants under Nasdaq listing rule
Feb 29
1:00am ET
New Regulation Risk for BioCryst Pharmaceuticals – What’s the Latest?
Feb 28
1:00am ET
Analysts’ Top Healthcare Picks: BioCryst (BCRX), Cytokinetics (CYTK)
Feb 27
5:08pm ET
BioCryst files automatic mixed securities shelf
Feb 27
7:11am ET
Analysts’ Top Healthcare Picks: BioCryst (BCRX), Veracyte (VCYT)
Feb 27
6:30am ET
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), TransMedics Group (TMDX) and MoonLake Immunotherapeutics (MLTX)
Feb 27
5:50am ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), BioCryst (BCRX) and Veeva Systems (VEEV)
Feb 27
3:28am ET
BioCryst (BCRX) Receives a Hold from Barclays
Feb 26
2:05pm ET
Buy Rating Affirmed on BioCryst’s Strong Orladeyo Sales and Path to Profitability
Feb 26
11:25am ET
Buy Rating Affirmed for BioCryst Pharmaceuticals on Orladeyo’s Success and Strong Growth Prospects
Feb 26
7:22am ET
Biocryst Pharmaceuticals Enhances Report with Exhibit 99.1
Feb 26
7:05am ET
BioCryst sees 2024 ORLADEYO revenue $380M-$400M
Feb 26
7:03am ET
BioCryst reports Q4 EPS (31c), consensus (24c)
Feb 23
7:11am ET
BioCryst presents real-world data on ORLADEYO
Feb 19
4:07pm ET
BioCryst Pharmaceuticals announces launch of ORLADEYO in Italy
Feb 02
7:04am ET
BioCryst reports inducement grants under Nasdaq listing rule
Jan 23
7:22am ET
Pharvaris price target raised to $13 from $11 at BofA
No recent press releases are available for BCRX
BCRX Financials
Key terms
Ad Feedback
BCRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BCRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
